reason report
zinbryta come end abbvi ambit
bottom line earlier morn announc
world-wide discontinu market long-act relaps
multipl sclerosi product zinbryta daclizumab less two
year regulatori approv updat come result
increas report inflammatori advers event brain
specif enceph meningo-enceph
addit advers event previous prompt initi
comprehens pharmacovigil investig european
medicin agenc ema safeti profil zinbryta alway
liabil commerci viabil drug alreadi
clear black box warn sever liver injuri immun
mediat disord disclosur morn
suggest decis remov zinbryta market
voluntari choic made manufactur given risk/benefit
profil limit commerci adopt drug due restrict
label zinbryta compris million million total
revenu forecast respect
collabor agreement record
us sale record sale outsid us cumul
report million ex-u sale zinbryta sinc
approv specif disclos us revenu
like million total estim zinbryta
like encompass global ms market
doesnt matter much either compani outlook financi
rais question judgement behind invest
daclizumab develop indic first place
daclizumab signific liabil outset never show
suffici efficaci justifi complex risk use
daclizumab look like inferior equal danger version
tysabri without overwhelm efficaci ultra-pot ms
treatment lemtrada drug made sens
back potenti failur tysabri drug pml risk
continu escal drug door-open
neurolog franchis opportun begin build portfolio
ms categori compani lost million dollar
develop commerci program
lack return invest reflect advers overal
follow announc remov zinbryta
revenu forecast result decreas
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
ms product sale forecast reduct total revenu
forecast futur year made chang
model revenu forecast modestli recent
consensu futur year revis earn forecast
consensu price target
previous result remov zinbryta relat revenu
reiter market perform rate stock
also remov revenu zinbryta abbvi
compani model result immateri effect total
revenu earn forecast compani remain roughli
line recent consensu total revenu futur year
slightli recent consensu earn
slightli despit neglig effect
remov zinbryta forecast updat compani
balanc sheet cash flow statement recent file
follow earn report price target chang
previous maintain market perform rate abbvi
zinbryta sale ou sale
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
price target stock rate market perform
success transit corpor ownership success independ
biopharmaceut compani mani best featur biotech pharma
resourc expertis infrastructur diversif larg pharma competitor
specialti product profil growth rate matur biotechnolog compani abbvi
remain highli depend singl franchis humira sale total
sale suggest us valuat still discount compar
diversifi peer us biosimilar settlement competitor mp appear
reassur investor fear biosimilar entri exagger invalid expect
oncolog product imbruvica venclexta becom signific product
gener revenu compani next-gener hcv
regimen boost market share consider declin market look
compani array promis late-stag clinic medicin oncolog inflamm
metabol diseas product contribut revenu growth
unlik materi dilut massiv headwind face biosimilar enter
market compet humira
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani
mid-term growth tail risk rhhbi sni nv celg
averag consensu ep multipl appli current ep estim
give valu use revenu multipl similar
compani consensu sale appli revenu estim
give valu lastli dcf valuat given wacc
termin cash flow growth rate begin humira biosimilar entri give
present valu averag three method current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi assum oper margin increas current level
toward fail reach sustain level would advers affect
forecast valuat also compani remain highli lever commit grow
dividend reduct forecast ebitda due neg busi trend would place
compani capit alloc strategi dividend growth risk opportun upsid
expect includ stronger-than-expect price volum share humira
emerg tangibl demand underappreci element compani early-to-
mid stage pipelin asset potenti label expans opportun late stage opportun
price target rate stock market perform
lead develop brand medicin treatment multipl sclerosi ms
contribut compani revenu today see market flux
new entrant increas reimburs challeng dampen outlook franchis
resourc research remain forefront categori
view still like lose share price time face flat-to-declin sale second
key driver compani profit share roch sale rituxan successor
antibodi contribut revenu profit see modest growth
cash flow stream given declin profit share competit challeng
categori reduct ocrevu growth initi launch year third driver
launch spinraza revenu opportun sma spinal muscular
atrophi therapi consid spinraza one import excit new product
launch sector anticip slow revenu growth us patient start becom
harder find launch impact combin effect labori insur
reimburs process restrict coverag age diseas type logist associ
deliv three induct intrathec inject interest part
pipelin novel medicin seriou neurolog diseas field one industri
leader could unlock tremend valu one first diseas modifi treatment
catastroph ill alzheim diseas amyotroph later sclerosi al
parkinson diseas unfortun pivot trial medicin riski expens
slow result trial emerg late leav limit
upsid stock immedi futur
price target base simpl averag three approach
believ reason basi valu stock today approach price
earn price sale dcf price earn approach appli current
multipl ep ep forecast discount result
valu back one year compani cost capit one-year price target
price sale approach use current averag price sale slow grow larg
cap biopharma stock nvo appli revenu
forecast price lastli dcf take present valu
forecast annual free cash flow assum valu termin
cash flow base termin growth rate discount compani cost
capit present valu averag approach current one year
price target
risk view outlook valuat includ major chang price
reimburs coverag label compani exist treatment multipl sclerosi
tysabri avonex plegridi tecfidera zinbryta success develop rapid market share
gain competitor product class success gener challeng
tecfidera intellectu properti posit alter ahead expect risk includ
disappoint question result on-going trial import develop
program particularli aducanumab opportun better perform valu includ
strong result mid-stag pipelin includ novel pain treatment raxatrigin
anti-lingo myelin restor program success progress compani co-develop
alzheim diseas treatment eisai ban
million
leerink partner research compani file
million
sale
 total revenu
sg total revenu
profit share total revenu
leerink partner research compani file
analysi stock price leerink target biogen idec
method current larg cap healthcar biopharma forward ep multipl
leerink adjust ep estim pre aducanumab launch
averag larg cap healthcar ep yr compound-annual-growth-rate multipl ep
impli price base current multipl appli ep estimate
capit
number year discount
present valu per share
impli price base ep
leerink estim present valu flow
estim net debt
estimate averag dilut share count mid
leerink project revenu pre- aducanumab launch
impli enterpris valu multipl
capit
number year discount
impli valu
per share valu
averag method
sourc leerink partner research compani file factset
million
leerink partner research compani file
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep rhhbi sni celg
leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
mid-term growth tail risk nv azn celg
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current leerink dcf marketed/l stage program
sourc leerink partner estim compani file factset
